David Maag
Impact in
- Hepatology top 2%
- Hepatitis C virus research
- Oncology top 2%
- PARP inhibition in cancer therapy
Papers in
-
- RNA and protein synthesis mechanisms 10
- RNA Research and Splicing 7
- RNA modifications and cancer 6
- DNA Repair Mechanisms 4
- Oncology 24
- PARP inhibition in cancer therapy 16
- Cancer Treatment and Pharmacology 8
- Co-authors
- Jon R. Lorsch (10 shared papers)Mikkel A. Algire (8 shared papers)Craig E. Cameron (3 shared papers)Weidong Zhong (2 shared papers)Johnson Y. N. Lau (2 shared papers)Zhi Hong (2 shared papers)Raul Andino (1 shared paper)Shane Crotty (1 shared paper)
- Journals
- Journal of Clinical Oncology (8 papers)Journal of Thoracic Oncology (4 papers)Annals of Oncology (4 papers)Cancer Research (3 papers)Molecular Cell (3 papers)
- Partner nations
- United StatesAustraliaFrance
In The Last Decade
David Maag
57 papers receiving 4.7k citations
David Maag's Hit Papers
Peers
Comparison fields: 5 of 114
- Hepatology 427
- Oncology 1.2k
- Molecular Biology 2.7k
- Cancer Research 456
- Infectious Diseases 458
Countries citing papers authored by David Maag
This map shows the geographic impact of David Maag's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Maag with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Maag more than expected).
Fields of papers citing papers by David Maag
This network shows the impact of papers produced by David Maag. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Maag. The network helps show where David Maag may publish in the future.
Co-authors
The 25 scholars most cited alongside David Maag, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 59 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen Hit paper breakdown → | 2000 | 674 |
| 2 | Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial Hit paper breakdown → | 2018 | 545 |
| 3 | 2010 | 308 | |
| 4 | 2007 | 263 | |
| 5 | 2001 | 242 | |
| 6 | 2015 | 207 | |
| 7 | 2005 | 195 | |
| 8 | 2018 | 180 | |
| 9 | 2008 | 165 | |
| 10 | 2014 | 157 | |
| 11 | 2005 | 156 | |
| 12 | 2011 | 149 | |
| 13 | 2007 | 135 | |
| 14 | 2002 | 124 | |
| 15 | 2011 | 116 | |
| 16 | 2002 | 105 | |
| 17 | 2000 | 100 | |
| 18 | 2011 | 98 | |
| 19 | 2007 | 96 | |
| 20 | 2020 | 94 |
About David Maag
David Maag is a scholar working on Molecular Biology, Oncology, Pulmonary and Respiratory Medicine, Genetics and Radiology, Nuclear Medicine and Imaging, having authored 59 papers that have together received 4.8k indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (16 papers), RNA and protein synthesis mechanisms (10 papers), Cancer Treatment and Pharmacology (8 papers), RNA Research and Splicing (7 papers), Advanced Breast Cancer Therapies (6 papers), RNA modifications and cancer (6 papers), DNA Repair Mechanisms (4 papers) and BRCA gene mutations in cancer (4 papers). The work is most often cited by research in Hepatology (427 citations), Oncology (1.2k citations), Molecular Biology (2.7k citations), Cancer Research (456 citations) and Infectious Diseases (458 citations). David Maag has collaborated with scholars based in United States, Australia and France. Frequent co-authors include Jon R. Lorsch, Mikkel A. Algire, Craig E. Cameron, Weidong Zhong, Johnson Y. N. Lau, Zhi Hong, Raul Andino, Shane Crotty, Jamie J. Arnold and Christie A. Fekete. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Annals of Oncology, Cancer Research and Molecular Cell.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.